A Practical Clinician's Guide to Identifying the Metabolic, Immune, and Inflammatory Milieu
Dr. Greg Fors, Chief Science Officer, BioSpec Nutritionals
Modern laboratory medicine gives clinicians an extraordinary amount of information. The problem is that we often look at that information one biomarker at a time. Glucose becomes a diabetes marker. ApoB becomes a cardiovascular marker. hsCRP becomes an inflammation marker. A CBC is reviewed for anemia, infection, or hematological disease and then frequently filed away.
Human physiology does not operate in separate compartments.
Insulin resistance affects adipose tissue, liver metabolism, mitochondrial function, endothelial biology, and inflammatory signaling. Visceral adipose tissue releases inflammatory mediators. Oxidative stress can modify lipoproteins and injure vascular structures. Activated immune cells generate reactive oxygen species and inflammatory mediators. Platelets participate not only in coagulation but also in inflammatory, immune, and vascular signaling.
Metabolism affects immunity, and immunity affects metabolism.
This interconnected biology is the foundation of immunometabolism. It gives clinicians an opportunity to use relatively inexpensive laboratory measurements to look beyond individual diseases and begin defining the patient's metabolic, inflammatory, immune, oxidative, and vascular milieu.
The goal is not simply to identify disease after it develops. The goal is to identify the physiology that precedes, accompanies, and perpetuates disease.
Each factor can add another log to the fire. The clinically meaningful question is what happens when the combined burden exceeds that individual's capacity to compensate.
That is the biological environment we want to measure.
ASSESS → PERSONALIZE → TRACK
A practical immunometabolic strategy can be reduced to three steps. Assess the dominant metabolic, inflammatory, oxidative, nutritional, and vascular abnormalities. Personalize lifestyle, nutritional, nutraceutical, and when appropriate pharmacological interventions around the physiology actually present. Then track those biomarkers to determine whether the biological environment is changing.
One measurement is a photograph. Serial measurements give us a movie.
An immunometabolic assessment can include fasting insulin and glucose, HOMA-IR, HbA1c and triglycerides; ApoB and Lp(a); hsCRP, ESR and fibrinogen; CBC with differential; NLR, SII and SIRI; and, when clinically appropriate, MPO, Lp-PLA2, oxidized LDL, ferritin and iron studies, vitamin D, RBC magnesium, omega-3 index and AA:EPA ratio.
But some of the most useful information may already be sitting in laboratory data we routinely obtain.
Your CBC Is Telling You More Than You Think
A CBC with differential gives us neutrophils, lymphocytes, monocytes, and platelets. These are not simply numbers used to rule out infection or hematological disease. They represent interacting components of innate immunity, adaptive immunity, inflammation, vascular signaling, and tissue repair.
From these routinely measured cells we can calculate three remarkably simple indices: NLR, SII, and SIRI.
There is no additional blood draw. There is no expensive specialty assay. The information is already there.
The literature surrounding these indices has expanded rapidly across obesity, metabolic syndrome, cardiovascular disease, diabetes, inflammatory disorders, cancer, and mortality.[1-4] Large healthy-population studies have also begun establishing reference distributions for NLR and SII.[5,6]
Add HOMA-IR and TyG, and the clinician now has five inexpensive calculations providing complementary windows into immune-inflammatory and metabolic physiology.
The following box is designed to be used at the desk while reviewing laboratory results.
CLINICIAN'S IMMUNOMETABOLIC CALCULATION BOX
NLR, Neutrophil-to-Lymphocyte Ratio
FORMULA
NLR = Neutrophils ÷ Lymphocytes
Example: Neutrophils 3.0 ÷ Lymphocytes 2.0
NLR = 1.5
Practical preventive target: approximately 1.0–2.0
Healthy-adult central value: approximately 1.65
What does it tell us? NLR reflects the relationship between neutrophil-mediated innate inflammatory activity and lymphocyte-related adaptive immunity.
Higher NLR: As NLR moves above approximately 2, look more closely for inflammatory, metabolic, infectious, or physiological stressors and for concordance with the rest of the biomarker pattern. Values above approximately 3 are increasingly outside the favorable physiological zone.
Lower NLR: An NLR around 1–2 generally reflects a favorable neutrophil-to-lymphocyte balance. Very low values should still be checked against the actual cell counts to exclude neutropenia or abnormal lymphocytosis.
SII: Systemic Immune-Inflammation Index
FORMULA
SII = Platelets × Neutrophils ÷ Lymphocytes
Example: Platelets 225 × Neutrophils 3.0 ÷ Lymphocytes 2.0
SII = 338
Practical preventive target: approximately 300–400 or lower
What does it tell us? SII combines three important systems: neutrophil-mediated innate inflammatory activity, lymphocyte-related adaptive immunity, and platelet-associated inflammatory and thrombo-inflammatory signaling.
Higher SII: Suggests increasing systemic immune-inflammatory activity, particularly when higher neutrophils and/or platelets coexist with relatively lower lymphocytes. In a large U.S. population study, SII >655.6 was associated with higher all-cause and cardiovascular mortality compared with the lowest group.
Lower SII: Generally reflects a more favorable immune-inflammatory balance. In that same U.S. cohort, SII <335.4 represented the lowest comparison group.
Practical clinical goal: When the individual CBC components are healthy, an SII around the low-to-mid 300s is a reasonable preventive target zone.
SIRI: Systemic Inflammation Response Index
FORMULA
SIRI = Neutrophils × Monocytes ÷ Lymphocytes
Example: Neutrophils 3.0 × Monocytes 0.4 ÷ Lymphocytes 2.0
SIRI = 0.60
Practical preventive target: approximately ≤0.7
What does it tell us? SIRI combines neutrophils and monocytes, two major components of innate immunity, with lymphocyte-related adaptive immunity. Monocytes are particularly important because they can migrate into tissues and differentiate into macrophages involved in adipose inflammation, vascular disease, tissue injury, and repair.
Higher SIRI: Suggests greater innate immune-inflammatory activity relative to lymphocyte representation. Values moving above approximately 1.0 deserve increasing attention to the overall inflammatory/metabolic picture. In a large U.S. cohort, SIRI >1.43 was associated with higher all-cause and cardiovascular mortality.
Lower SIRI: Generally indicates a more favorable innate-to-adaptive immune relationship. In the same cohort, SIRI <0.68 represented the lowest comparison group.
HOMA-IR: Homeostatic Model Assessment of Insulin Resistance
FORMULA
HOMA-IR = Fasting insulin (µIU/mL) × Fasting glucose (mg/dL) ÷ 405
Example: Fasting insulin 4.5 × fasting glucose 90 ÷ 405
HOMA-IR = 1.0
Practical preventive target: approximately ≤1.0
Early metabolic concern: approximately >1.5
Increasing insulin resistance: approximately ≥2.0–2.5
What does it tell us? HOMA-IR asks a question glucose alone cannot answer: How much insulin is required to maintain that fasting glucose?
Higher HOMA-IR: Indicates progressively greater insulin resistance and compensatory insulin demand.
Lower HOMA-IR: A value around 1.0 or lower, when accompanied by healthy fasting glucose and insulin, represents excellent fasting insulin sensitivity.
This is why fasting insulin matters. A glucose of 95 mg/dL maintained with an insulin of 4 µIU/mL is metabolically different from the same glucose maintained with an insulin of 18 µIU/mL.
TyG, Triglyceride-Glucose Index
FORMULA
TyG = ln [Fasting triglycerides (mg/dL) × Fasting glucose (mg/dL) ÷ 2]
Example: Triglycerides 70 × glucose 90 ÷ 2 = 3,150
ln(3,150) = TyG 8.05
Practical favorable target: approximately <8.3–8.5
Increasing metabolic concern: approximately ≥8.5
Many metabolic-syndrome studies identify discriminatory values around 8.7–8.9
What does it tell us? TyG integrates glucose regulation with triglyceride metabolism and provides another inexpensive window into insulin resistance and cardiometabolic dysfunction.
Higher TyG: Suggests increasing insulin resistance and metabolic burden.
Lower TyG: Indicates a more favorable triglyceride-glucose metabolic phenotype.
Important: These values use the formula shown above. Alternative scaling conventions for TyG appear in the literature and should not be mixed.
PUT THE PATTERN TOGETHER
FAVORABLE PATTERN
NLR ≈ 1–2
SII ≈ 300–400 or lower
SIRI ≈ ≤0.7
HOMA-IR ≈ ≤1.0
TyG ≈ <8.3–8.5
INCREASING IMMUNOMETABOLIC BURDEN
NLR ↑ + SII ↑ + SIRI ↑ + HOMA-IR ↑ + TyG ↑
Now add:
Fasting insulin ↑ + Triglycerides ↑ + hsCRP ↑ + ApoB ↑
At that point we are no longer looking at an isolated abnormal laboratory value.
We are looking at an immunometabolic phenotype.
These are practical preventive/physiological targets derived from healthy-population distributions, observational risk data, and metabolic literature. They are not universal laboratory diagnostic cutoffs. Always examine the underlying absolute cell counts and clinical context.
The Pattern Is More Important Than Any One Number
That box summarizes the central concept of this paper.
Imagine two patients with identical HbA1c values of 5.5%.
The first has fasting insulin of 4 µIU/mL, HOMA-IR of 0.9, triglycerides of 65 mg/dL, NLR of 1.5, SII of 330, SIRI of 0.6, low hsCRP, and ApoB of 75 mg/dL.
The second has fasting insulin of 15 µIU/mL, HOMA-IR of 3.3, triglycerides of 180 mg/dL, NLR of 3.1, SII of 700, SIRI of 1.5, elevated hsCRP, and ApoB of 115 mg/dL.
Their HbA1c says they look similar.
Their biology says otherwise.
The second patient is displaying a coordinated pattern of hyperinsulinemia, insulin resistance, altered lipid metabolism, atherogenic particle burden, and immune-inflammatory activation.
That is what immunometabolic assessment allows us to see.
Look Earlier Than HbA1c
Compensatory hyperinsulinemia can maintain acceptable glucose concentrations for years. A patient may therefore have a fasting glucose and HbA1c that attract little attention while insulin resistance, visceral adiposity, fatty liver, hypertriglyceridemia, hypertension, and inflammatory signaling are developing underneath.
Fasting insulin changes the conversation.
HOMA-IR then integrates insulin with glucose. TyG integrates triglycerides with glucose. NLR, SII, and SIRI add information about immune-inflammatory biology.
Suddenly we are no longer asking only:
"Is this patient's glucose abnormal?"
We are asking:
"What is this patient's metabolic and immune system having to do to maintain apparent normality?"
That is a much more useful clinical question.
Add the Rest of the Immunometabolic Dashboard
Once the foundational calculations are in place, additional biomarkers can deepen the picture.
hsCRP, ESR, and fibrinogen provide complementary information regarding systemic inflammatory activity. ApoB quantifies atherogenic particle burden, while Lp(a) identifies an important largely genetically determined cardiovascular risk component.
In selected patients, MPO, Lp-PLA2, and oxidized LDL can provide additional information concerning vascular inflammatory and oxidative biology.
Nutritional biomarkers can identify another layer of modifiable physiology. Vitamin D, RBC magnesium, ferritin and iron studies, omega-3 index, and AA:EPA ratio can help identify deficiencies, imbalances, or nutritional patterns capable of influencing metabolic and inflammatory biology.
The objective is not to order everything.
Measure what helps answer the physiological question.
Now Treat What You Measured
Once the phenotype becomes visible, treatment becomes more rational.
A patient dominated by hyperinsulinemia and insulin resistance requires a different emphasis from someone dominated by inflammatory activation, oxidative stress, mitochondrial dysfunction, or nutritional insufficiency. Many patients demonstrate several simultaneously.
This is where the concept of total biological burden becomes clinically useful.
Ultra-processed foods, added sugars, refined and ground carbohydrates, visceral adiposity, insulin resistance, physical inactivity, poor sleep, smoking, excessive alcohol, dysbiosis, micronutrient insufficiency, chronic infection, autoimmune activity, psychological stress, and environmental exposures can each add another log to the fire.
The clinician's job is to identify as many of those logs as possible and start removing them.
Lifestyle First
Lifestyle is not the preliminary treatment before the "real" treatment.
Lifestyle is the foundation of the treatment.
When insulin resistance is present, remove ultra-processed foods, added sugars, and refined/ground carbohydrate products. Emphasize nutrient-dense whole foods, adequate protein, non-starchy vegetables, nuts, seeds, and healthy fats according to the patient's individual needs.
Increase skeletal-muscle glucose disposal through resistance training and regular physical activity. Address visceral adiposity, inadequate sleep, smoking, excessive alcohol, chronic stress, and other identifiable drivers.
No nutraceutical can overcome a persistently destructive biological environment.
But once we are changing that environment, targeted nutritional support can be matched to the physiology we measured.
Targeted Nutritional Support: Match the Intervention to the Pattern
Insulin-Resistant / Hyperinsulinemic Pattern
When fasting insulin, HOMA-IR, TyG, triglycerides, or postprandial glucose suggest impaired insulin signaling, several nutraceuticals can support complementary aspects of glucose and insulin physiology.
Berberine influences multiple metabolic pathways, including AMPK-related signaling and hepatic glucose metabolism. Mulberry leaf standardized for DNJ can reduce intestinal carbohydrate digestion through alpha-glucosidase inhibition. Gymnema sylvestre has evidence supporting glucose metabolism. Cinnamon extracts, banaba-derived corosolic acid, chromium, and biotin provide additional complementary metabolic support.
Biospec Glucose-IR combines these approaches into a multi-target formula designed to support insulin and glucose physiology.
Structure-function support: Biospec Glucose-IR is intended to support healthy insulin and glucose physiology.
The objective is not simply to lower glucose.
The objective is to improve the metabolic environment producing the glucose.
Inflammatory / Immune-Activated Pattern
When hsCRP, fibrinogen, NLR, SII, SIRI, symptoms, and clinical findings point toward an inflammatory phenotype, targeted botanical support can complement removal of the underlying inflammatory drivers.
Curcumin phytosome influences multiple inflammatory signaling pathways. Boswellia serrata standardized for active boswellic acids provides complementary modulation of inflammatory pathways. Ginger influences inflammatory and oxidative signaling through additional mechanisms.
Biospec Inflam-95 combines these botanical strategies to provide broad nutritional support for inflammatory physiology.
Structure-function support: Biospec Inflam-95 is intended to provide broad nutritional support for inflammatory physiology.
Again, the goal is not simply to force CRP or SII downward.
Ask why they are elevated, and treat that biology.
Oxidative / Mitochondrial Pattern
Oxidative stress and mitochondrial dysfunction frequently travel with insulin resistance and chronic inflammation.
N-acetylcysteine supplies cysteine for glutathione synthesis. R-alpha-lipoic acid participates in mitochondrial metabolism and cellular redox cycling. Acetyl-L-carnitine supports mitochondrial fatty-acid transport and energy metabolism. Coenzyme Q10 participates directly in mitochondrial electron transport while contributing antioxidant activity.
Biospec Mito-Detox III combines these nutrients to support interconnected mitochondrial, antioxidant, and redox systems.
Structure-function support: Biospec Mito-Detox III is intended to support interconnected mitochondrial, antioxidant, and redox systems.
This is a systems-biology approach: multiple targeted nutritional "tuning hammers" addressing different components of the same disturbed physiological network.
Nutritional Resilience
Omega-3 fatty acids, magnesium, vitamin D, zinc, selenium, and other nutrients can be individualized according to diet, laboratory findings, medications, and clinical circumstances.
The omega-3 index is an excellent example of personalized nutrition.
Measure → intervene → remeasure.
Don't assume that two patients taking the same amount of fish oil achieve the same erythrocyte EPA+DHA level. Measure the biological result.
Close the Loop: Measure Again
Suppose several months after intervention a patient's results change:
Fasting insulin: 18 → 7 µIU/mL
HOMA-IR: 4.1 → 1.5
Triglycerides: 190 → 92 mg/dL
hsCRP: 4.2 → 1.1 mg/L
NLR: 3.2 → 1.9
SII: 720 → 430
SIRI: 1.8 → 1.0
These are illustrative numbers, but look at what the pattern tells us.
We are not simply watching glucose improve.
We may be watching a coordinated shift in insulin signaling, lipid metabolism, systemic inflammation, and immune-cell relationships.
That is the purpose of serial immunometabolic assessment.
Measure the biology → change the biology → measure it again.
Use the Numbers Intelligently
NLR, SII, SIRI, HOMA-IR, and TyG exist along a continuum. Their values are influenced by age, population, metabolic status, and clinical circumstances. Acute infection, surgery, trauma, glucocorticoids, and hematological abnormalities can obviously alter leukocyte or platelet measurements.
That does not diminish their value. It tells us to practice medicine rather than treat a spreadsheet.
The preventive targets in our calculation box should therefore be viewed as physiological guideposts, not absolute diagnostic boundaries.
The important question is whether multiple independent biomarkers are telling the same biological story, and whether that story changes after treatment.
You Can't Treat What You Don't Measure!
Personalized medicine requires more than waiting until physiology deteriorates sufficiently to acquire a diagnostic label.
Fasting insulin can reveal metabolic stress hidden behind acceptable glucose. HOMA-IR tells us how much insulin is required to maintain that glucose. TyG gives us another window into insulin resistance. ApoB reveals atherogenic particle burden. hsCRP and fibrinogen reveal inflammatory activity.
And NLR, SII, and SIRI can transform information already sitting in an ordinary CBC into a practical window into the relationship between immunity, inflammation, and metabolism.
None tells the entire story.
Together, they begin to describe the patient.
Measure the physiology. Identify the pattern. Remove the drivers. Support the systems under stress. Then measure again.
ASSESS → PERSONALIZE → TRACK
Because you can't treat what you don't measure.
References
Biospec Nutritionals: Clinical Education Series
For healthcare-professional education. Practical target values presented here are physiological/preventive guideposts rather than universal diagnostic thresholds. Laboratory findings should be interpreted within the patient's complete clinical presentation.
Bottom Line
Measure the physiology. Identify the pattern. Remove the drivers. Support the systems under stress. Then measure again.
Comprehensive Medical Disclaimer
This educational material is intended for healthcare professionals and general informational purposes only. It is not medical advice, diagnosis, or treatment, and it does not replace evaluation by a qualified healthcare professional. Laboratory findings and nutritional interventions should be interpreted within the patient's complete clinical presentation, medical history, medications, and individual needs. Do not start, stop, or change a treatment or supplement regimen without consulting an appropriate healthcare professional.
#ImmunometabolicHealth #InsulinResistance #FunctionalMedicine #EvidenceBasedNutrition #ClinicalNutrition #BioSpecNutritionals #Immunometabolism #ProfessionalGradeSupplements